At the heart of lineage commitment within the adaptive immune response is the intrinsic genetic plasticity of the naive peripheral T lymphocyte (T cell). Primary activation by presentation of cognate antigen is coupled to rapid T-cell cycling and progressive epigenetic changes that guide the cell down distinct T-cell lineages, either effector (Th1, Th2, Th17) or tolerogenic (Treg). Fate choice is influenced both by strength of the priming activation signal and by cues from the micro-environment that are integrated with lineage-specific gene expression profiles, eventually becoming hard-wired in the fully differentiated cell. The micro-environmental cues include cytokines, and the discovery that leukaemia inhibitory factor (LIF) and interleukin (IL)-6 counter-regulate development of the Treg and Th17 lineages places LIF within the core regulatory circuitry of T cells. I first summarise current understanding of LIF and the LIF receptor in the context of T cells. Next, the central relevance of the LIF/IL-6 axis in immune-mediated disease is set in the context of (i) a new nano-therapeutic approach for targeted delivery of LIF and (ii) MARCH-7, a novel E3-ligase discovered to have a central mechanistic role in LIF-mediated T-cell biology, functioning as a rheostat-type regulator of endogenous LIF-signalling.
Introduction
Leukaemia inhibitory factor (LIF) is a highly conserved pleiotrophic cytokine. A direct role for LIF in specific regulation of adaptive immune tolerance was first identified in a genome-wide subtractive analysis of allo-tolerance, versus allo-rejection, ex vivo.
1 Only 12 factors out of over 30 000 candidates proved to be specific for tolerance (Table 1) . One of the 12 was LIF, 2 another MARCH-7-previously known as axotrophin and subsequently identified as an E-3 ligase that regulates the LIF receptor. These results led to the discovery that LIF has a pivotal role in T-cell immunity. The intention of this overview is to bring focus on LIF in T-cell biology and on LIF's potential as a therapeutic: here compound therapeutic benefit is anticipated where LIF will act not only in support of immune tolerance but also as a growth factor to promote tissue repair, such as in promotion of neurogenesis in treatment of autoimmune disease of the central nervous system. Other more general reviews concerning LIF include a broad discussion entitled 'The Unsolved Enigmas of Leukemia Inhibitory Factor' from Don Metcalf, who emphasises that loss of the LIF receptor is embryo lethal: loss of LIF itself is not, due to promiscuity within the LIF family of cytokines. 3 More focused is a review from Auernhammer and Melmed 4 that covers the neuro-immune modulatory activity of LIF on endocrine function: this is complemented by a recent genome-wide study of LIF response genes associated with the response to stress at the hypothalamo-pituitaryadrenal axis either alone or in conjunction with glucocorticoids. 5 From a more selective neuro-immune angle, Paul Patterson's 6 group has reviewed LIF and other neuropoietic cytokines in the context of neural development, plasticity, disease and injury.
Arguably, the most important role of LIF is to introduce and/or maintain epigenetic plasticity within the genome: thus LIF is permissive for epigenetic flexibility. This flexibility is greatest in stem cells where LIF functions in concert with Nanog, a core stem cell transcription factor that, under the influence of LIF, choreographs pluripotency and self-renewal in mouse embryonic stem cells (for example, see refs 7-12) . By titrating exposure of stem cells to immobilised LIF, quantitative experiments from Zandstra's group 13 have demonstrated concentration dependency for LIFmediated control of 'stemness'. As cell lineages become established, epigenetic plasticity decreases concomitant with progressive hard-wiring of gene expression profiles through sequential precursor cell stages, culminating in the terminally differentiated cell. Once thought to be irreversible, Takahashi and Yamanaka's 14 discovery that the genome of a differentiated cell can re-establish a pluripotent status following transfection with core stem cell transcription factors argues for the principle that a central property of nucleated cells is the potential of epigenetic plasticity-albeit decreasing as differentiation increases. Of note, even adult lymphocytes may be induced to express core stem cell genes. 15, 16 This overview introduces various features that would be in accord with LIF operating within the naive peripheral T cell to maintain a level of epigenetic plasticity for optional response pathways to incoming primary T-cell antigen receptor-linked activation signals. It is envisaged that these response pathways will in turn determine the fate of both LIF expression and LIF responsiveness during ensuing lineage specification. For example, in Treg LIF continues to have a role, further promoting the Treg lineage, while in TH17 cells LIF activity becomes effectively shut down: thus, by regulating LIF, T-cell fate is itself also regulated.
Background to LIF in T lymphocyte biology
LIF is a member of the IL-6-type cytokine family LIF is a pleiotrophic cytokine of the 4-a-helix bundle family that includes interleukin-6 (IL-6), LIF, oncostatin M, ciliary neurotrophic factor, IL-11 and cardiotrophin-1. 17, 18 LIF is encoded by a single copy gene on chromosome 22q12 in humans, and is tightly linked to the gene encoding oncostatin M where close commonalities between LIF and oncostatin M structure support the notion of a common gene source. There is 75% homology with the murine LIF gene (chromosome 11), with homology being predominant in the coding domains: across species, the 5 0 flanking region of the major transcriptional start site is conserved. The LIF protein is a monomeric glycoprotein of 180 amino-acid residues and includes a disulphide link. The unglycosylated protein has an apparent molecular weight of 20-25kDa and retains biological activity. Structurally, the tertiary folding of four long a-helices creates a longchain cytokine closely resembling granulocyte colonystimulating factor.
Transgenic mice specifically overexpressing LIF in T cells show that LIF has an important role in maintaining a functional thymic epithelium that will support proper T-cell maturation. 19 These animals display B-cell hyperplasia, polyclonal hypergammaglobulinemia and mesangial proliferative glomerulonephritis: in addition, thymic and lymph node abnormalities occur. In the thymus, cortical CD4 þ CD8 þ lymphocytes are lost while numerous B-cell follicles develop: peripheral lymph nodes contain a vastly expanded population of CD4 þ CD8 þ lymphocytes. The thymic epithelium is profoundly disorganised and is irreversibly altered, while transplantation studies indicate that nodal (but not thymic) abnormalities can be rescued by wild-type bone marrow. Transforming growth factor-b differentially modulates epidermal growth factor effects in human thymus, including the effects on LIF, 20 the expression of which increases with age and is associated with thymic atrophy. 21, 22 In the human Jurkat T lymphoma cell line, LIF gene expression is regulated by ets (E-twenty six) transcription factors. 23 Alternative splicing results in three forms of LIF The organisation of the LIF gene is complex. By alternative splicing of three alternative first exons to common second and third exons, LIF-D, LIF-M and LIF-T transcripts can occur, each being independently regulated. LIF-D transcripts encode only secreted proteins, and LIF-M may give rise to secreted LIF or persist as an intracellular protein. Secreted LIF-M can be active in the extracellular matrix. LIF-T is N-terminal truncated and lacks a secretion signal sequence, giving rise to intracellular LIF of 17kDa molecular weight. LIF-T Proteins detected by western blot of spleen cells from in vivo primed allo-tolerant, versus allo-rejected, mice following ex vivo stimulation with donor antigen measured at nine time points over a period of 5 days: for each sample cells were fractionated before analyses as indicated. 38 Different proteins were probed including cytokines, signal transducers and transcription factors. 2, 46, 67, 95 Those shown were specifically increased in, or were exclusive to, allo-tolerance.
overexpression induces apoptosis independent of the cell surface LIF receptor (LIF-R). For secreted LIF, however, binding to the LIF-R is necessary for activity. All three transcripts are raised in stem cells and progenitor cells. LIF-D and LIF-M are upregulated in response to the proinflammatory cytokines IL1-b and tumour necrosis factor. LIF-D and LIF-M also respond to signalling molecules active in growth and development, including glucocorticoids, estrodial, fibroblast growth factor-2 (FGF-2) and transforming growth factor-b1. 24 Overall, it is likely that each of the alternative forms of LIF serves distinct and biologically significant functions. 25 As discussed later, by varied expression levels of LIF-M in different tissues in the body, the micro-environment of T cells in those tissues will be influenced by the combination of LIF-M plus LIF-D.
The LIF receptor
The cytokine receptor gp130 is the shared signalling subunit of the IL-6 family of cytokines where gp130 homodimers transmit IL-6 signals. LIF shows a critical difference from IL-6 in that the LIF-R is composed of gp130/gp190 hetero-dimers. What regulates formation of gp130/gp130 homo-dimers, versus gp130/190 heterodimers, within the plasma membrane has been the subject of an elegant study of single cells from Gerhard MullerNewen and Peter Heinrich. 26 using fluorescence resonance energy transfer and bimolecular fluorescence complementation. Evidence for transient pre-formed gp130 homodimers, able to be stabilised by IL-6, was found. In contrast, the LIF ligand was required to drive gp130/gp190 heterodimer formation, first binding gp190 (the LIF-specific receptor subunit) then recruiting gp130. Figure 1 summarises a predicted model by which LIF and IL-6 signalling can be differentially controlled: this is based on that suggested by Muller-Newen and Heinrich. 26 LIF-mediated binding to the LIF receptor leads to activation of several pathways including: JAK/STAT (Janus kinase/signal transducer and activator of transcription); PI3-kinase (phosphoinositide 3-kinase)/Akt/ PKB activation; and MAPK (mitogen-activated protein kinase) cascades. Patterns of activation are cell-type specific and may be modulated by soluble receptors. 27 Ligand-specific utilisation of gp130-related receptors [28] [29] [30] [31] and the exchangeable nature of the receptor modules 32 contribute to regulation of LIF signalling at the receptor level. Cross-regulation between downstream pathways has recently been discussed by Niwa et al., 33 here in the context of embryonic stem cells but likely to also apply in principle to other cell types especially those showing epigenetic plasticity during developmental differentiation.
Un-stimulated naive T cells show very low gp130 and gp190 surface expression, but activation results in conversion to a gp130 high gp190
high phenotype within 48 h. 34 The commonality of the gp130 receptor subunit for both LIF and IL-6, versus the specificity of the gp190 subunit for LIF, would be permissive for receptor competition should gp190 become effectively high and gp130 become limiting. Accordingly, it has been suggested that regulation of gp190 may contribute to a mechanism to favour LIF signalling over IL-6 signalling in T cells. 16 
SOCS-3
In responding cells, LIF-induced signalling through the JAK/STAT3 pathway is tightly regulated by negative feedback. LIF-response genes include suppressor of cytokine signalling-3 (SOCS-3) that encodes the dominant suppressor of LIF-induced STAT3 signalling 35, 36 that acts mainly on gp130. 37 Such feedback regulation of a critical cytokine ensures balanced physiological responsiveness and permits changes in intensity of signal. Foxp3 is the Treg lineage-specific transcription factor and the subject of excellent reviews. [38] [39] [40] [41] [42] [43] LIF induces Foxp3 in activated naive CD4 T cells ( Figure 3 ). Foxp3 in turn may suppress transcription of SOCS-3, as evidenced by SOCS-3 deficiency in Treg, 44 a finding in accord with the discovery that SOCS-3 gene expression in Jurkat T cells is suppressed by wild-type FOXP3, but not by the delta-E251 mutant form of FOXP3 that lacks a DNA-binding domain. 45 Thus, reduced SOCS-3 may be permissive for more sustained LIF signalling that in turn promotes expression of FOXP3 46 providing a positive feedback loop between LIF and FOXP3 that includes repression of SOCS-3. Overexpression of SOCS-3 in Treg was found to remove the Treg phenotype and Treg-associated suppressive properties, 44 again in accord with a potential role for regulation of SOCS-3 by FOXP3 in Treg.
LIF in T cells
LIF is released from T cells in response to primary activation, including by the T-cell mitogen concanavalin A. 47, 48 Using LIF-deficient mice, Escary et al. 49 demonstrated that LIF is required to maintain survival of hematopoietic stem cells (but not their terminal differ- , 26 (A) shows the gp130 and gp190 receptor subunits within the plasma membrane (pm), where spontaneous gp130 homodimers are in equilibrium with discrete monomers. The upper part shows IL-6, in complex with soluble IL-6 receptor a, binding to and stabilising gp130 homodimers, leading to IL-6-driven signalling. The lower part shows LIF binding directly to gp190 monomers, followed by gp190/gp130/LIF complex formation and activation of LIF signalling. entiation) and that thymic T cells require LIF to respond to concanavalin A, an observation possibly linked to the finding that LIF is required to maintain a functional thymic epithelium. 19 For human lymphocytes, release of LIF appears to be specific to T cells and to CD4 þ T cells in particular. 50 In mice, LIF was increased in allotolerance ex vivo. Using isogenic clones of Th1, Th2 and Tr1/Treg, only Treg were the major source of LIF. 2 Recently it has been shown that activated human Treg also release high levels of LIF. 51 It is interesting to note that CD4 þ , but not CD8 þ , thymocytes promote embryo implantation 52 -a LIFdependent process somehow linked to p53 53 -and in human pregnancy cytokines including LIF produced by maternal T cells are thought to create a suitable microenvironment for preimplantation embryo development and maintenance of pregnancy. 54 At least some immuneprivileged sites are associated with an environment rich in LIF protein, including the brain and placenta: [55] [56] this is likely to reflect matrix-bound LIF-M. In marked contrast, IL-6 may be absent as illustrated in Figure 2 . It is possible that local expression of LIF, both via release from T cells plus local LIF-M within an immuneprivileged site, will create a relatively tolerogenic microenvironment associated with Treg lineage development and maintenance.
LIF has a key anti-inflammatory role in cutaneous inflammation 57 where, comparing LIF null mouse responses in the presence or absence of an adenoviral LIF vector, LIF was demonstrated to be an important regulator of IL-1b, IL-6, IL-2Ra and interferon-g (INFg). This is in accord with an earlier study where vectormediated delivery of LIF within skin allografts led to improved graft survival compared with vector-only controls. 58 A potential role of increased levels of IL-6 in human kidney graft rejection has been suggested 59 andgiven the opposing reciprocity between LIF and IL-6 as detailed later 34 -this may relate to the finding of a correlation between enhanced IL-6 signalling and poor primary kidney graft function in the clinic. 60 LIF delivered to CD4 þ cells via biodegradable PLGA nanoparticles guided the in vivo alloimmune response toward CD4 þ Foxp3 þ Treg, while treatment with anti-LIF had the opposite effect 34 demonstrating an allospecific, LIF-specific, effect. This places LIF at odds with IL-6 in terms of T-cell function, IL-6 being pro-inflammatory and a driver of TH17 lineage development in the presence of transforming growth factor-b. 61 Importantly, in vivo generation of TH17 cells has minimal effect on Treg cell numbers, 62 implying that reciprocity observed in vitro does not restrict the Treg population in vivo.
In autoimmune disease, a causative role for IL-6 is known, for example, in rheumatoid arthritis and inflammatory bowel disease, 63 in addition to being implicated in human multiple myeloma where constitutively elevated circulating IL-6 may occur. 64 Counter-active effects of IL-6 on self-tolerance have been demonstrated in a clinical study of psoriasis 65 where high IL-6 protein expression by CD31 þ endothelial cells and CD11c þ dermal dendritic cells in lesioned psoriatic skin was associated with dampened Treg function. IL-6-R and gp130 were significantly elevated in the psoriatic effector T cells compared with controls. Indeed, using T cells obtained from the patients, IL-6 was necessary and sufficient to reverse human T-cell suppression by Treg while anti-IL-6 restored Treg-mediated suppression.
Quintana et al. 66 examined the induction and evolution of an autoimmune response to a target tissue in which the microenvironment was modified by IL-6, using experimental autoimmune encephalitis (EAE) in mice to model human multiple sclerosis (MS). IL-6 production was genetically engineered for restriction to the cerebellum, and was found to redirect leukocyte trafficking away from the normally preferred antigenic site of the spinal cord. The cerebellar IL-6 markedly enhanced inflammatory cell accumulation, pathogenic plaques, and disease within the cerebellum: notably, there was only very mild inflammation in the spinal cord despite immunisation against myelin-oligodendrocyte glycoprotein (MOG). Overall it was shown that the local milieu of the central nervous system (CNS) tissue conditioned by IL-6 can dramatically influence the development of both auto-antigen-specific as well as nonspecific immune responses and associated pathology. A range of possible A LIF/IL-6 axis is linked to Treg versus TH17 lineage development LIF released during the ex vivo allo-tolerant response to donor was found to be associated with profound repression of INFg release and delayed kinetics of IL-6 release; 34, 67 in marked contrast, in allo-rejection, LIF was low while INFg rapidly reached ngml -1 levels-over 500-fold greater when compared with allo-tolerance. 34, 67 In follow-on studies, LIF was confirmed to induce specific suppression of INFg release following stimulation by Tcell mitogens. 46 Other groups later showed that IL-6, known to be associated with inhibition of allo-tolerance, 68 promotes differentiation of TH17 cells in the presence of transforming growth factor-b. 61 When exploring possible interactions between LIF and IL-6, a head-to-head study revealed that LIF and IL-6 function as polar opposites in CD4 þ T cells, 34, 69 as illustrated in Figure 3 . LIF directly promoted the Treg lineage-specific transcription factor, Foxp3, while simultaneously repressing TH17 lineage-specific genes including the transcription factor RORgt: conversely, IL-6 inhibited expression of Foxp3 and promoted RORgt. 34, 69 Thus a critical LIF/ IL-6 axis in T-cell lineage maturation was first identified, as modelled in Figure 4 .
Implications of the LIF/IL-6 axis
In considering LIF in T-cell biology it is necessary to also consider IL-6, given the intrinsic counter-regulatory relationship between the two. Sites of endogenous LIF expression, such as the placenta, testis and hippocampus within the CNS, are associated with immune privilege, likely to be linked to LIF providing an anti-inflammatory microenvironment and being able to promote Foxp3 in T cells. Conversely, an IL-6-rich environment-for example induced by an inflammatory lesion-will favour polarisation toward TH17-mediated immunity. Such counterregulation between local Treg cells will oppose local TH17 cells, as has been observed in models of Parkinson's disease. 70 Huntington's disease is triggered by mutant Huntingtin protein that is present throughout the body in addition to the CNS: pathogenic inflammatory immunity occurs and escalating levels of circulating IL-6 precede onset of clinical Huntington's disease symptoms. 71, 72 Accordingly, peripheral IL-6 is being considered as an early predictor of disease progression in asymptomatic carriers. [71] [72] Early warning will be important for potential treatment that may slow down the CNS disease pathology: a future question might be, can the pre-clinical stage be ameliorated by countering IL-6 activity?.
In a study of EAE, pre-existing autoimmune inflammation within the CNS, associated with IL-6 and tumour necrosis factor activity, could not be reversed by introduction of myelin-specific Treg. 73 However, others showed that blockade of IL-6 inhibited myelin-specific TH17 and TH1 cells in EAE. 74 Clearly, the respective levels of counter-opposing factors is critical: levels of IL-6 and inflammation within the micro-environment of diseased tissues need to be reduced for enhancement of a tolerogenic strategy that might be mediated-for example-by LIF. Notably, even in the very difficult model of allogeneic bone marrow grafting, blockade of IL-6 signalling using anti-IL-6 receptor augments Treg reconstitution and attenuates severity of graft versus host disease. 75 Thus not only can auto-antigen-driven inflammatory immune responses be reduced by IL-6 blockade, but auto-reactive Treg can be expanded: one means to enhance such induction of Treg would be delivery of LIF to the responding CD4 þ T cells. Indeed, in certain conditions LIF has added value, for example, being directly neuro-protective in EAE. When measuring cytokine responses to induced acute inflammatory demyelination, a strong induction of LIF transcription within the spinal cord was found. The importance of this LIF was revealed by antibody-mediated LIF neutralisation where a marked increase in severity of disease was found: this demonstrated that the endogenous LIF protects mature oligodendrocytes from demyelinating injury and cell death. 76 A link to T-cell-derived cytokines adding to this neuroprotective effect, and possibly also imposing immune tolerance, arises from a recent clinical trial where T cells of MS patients in remission have been shown to release neuro-protective factors in response to MOG, 77 see below.
Reversion of MS symptoms following lympho-depletion and homeostatic recovery
A key clinical discovery likely to underpin future approaches to MS therapy is the partial reversion of the MS-related immune phenotype following therapeutic depletion of peripheral CD52 þ cells. MS patients treated with alemtuzumab (a humanised anti-CD52 antibody also known as CamPath1-H) experienced an improvement in disability at 6 months that was sustained for at least 3 years. In contrast, patients treated with interferon b-1 suffered a steadily progressive disease. In the alemtuzumab arm of the study, homeostatic recovery of the T-cell population following therapeutic depletion appeared to permit, and/or promote, brain repair. Remarkably, this repair is linked to putative delivery of T-cell-derived neuropoietic cytokines to the CNS, as outlined below.
In the peripheral circulation, T cells from the alemtuzumab-treated MS patients were a direct source of increased amounts of neurotrophic factors including brain-derived neurotrophic factor, platelet-derived growth factor and ciliary neurotrophic factor (ciliary neurotrophic factor, a LIF-related cytokine): factor release was specific, being in response to stimulation by MOG. 
LIF and fate determination in T cells SM Metcalfe
Overall the study demonstrates (i) repair within the CNS of MS patients following alemtuzumab-mediated lymphocytic depletion; and (ii) subsequent contribution of neuro-protective MOG-reactive T cells to the CNS repair. 77 Given the neuroprotective effect of LIF in EAE 76 plus LIF's promotion of Treg-known to release LIF in response to antigenic stimulation-these patientderived MOG-reactive T cells are likely to be of the Treg lineage.
LIF as a therapy for MS
The therapeutic potential of LIF in MS is the subject of a very recent review by Slaets et al. 78 who note the crucial role played by LIF in (i) neuroprotection, (ii) axonal regeneration and (iii) preventing demyelination. The evidence includes lentiviral-mediated delivery of LIF to the CNS of adult mice: this protected against disease pathology, and was more efficacious than systemic delivery of recombinant LIF in ameliorating symptoms. 79 Gene delivery as a route to treatment of inflammatory demyelinating diseases is reviewed by Furlan et al. 80 although it needs to be noted that viral-mediated delivery encounters difficulty because of patient exposure to viral vector or foreign protein: this is avoided when LIF is delivered using biodegradable nanoparticles constructed from poly(lactic-co-glycolic acid) (PGLA), PGLA being the material used for clinical dissolving sutures.
Both LIF and retinoic acid promote differentiation of Treg: is there a mechanistic link? Before moving to the nanotherapeutic approach to LIF therapy, an alternative means to induce Treg needs to be considered. This employs all-trans retinoic acid (ATRA) where it has been reported that ATRA inhibits TH17 polarisation and enhances Foxp3 expression in CD4 þ T cells. 81, 82 Others have shown that ATRA promotes in vivo expansion of Foxp3 þ Tregs associated with suppression of INFg-producing T cells, though without affecting TH17 cells. 83 Recently reviewed by Noelle, 84 ATRA is a nuclear hormone that binds the retinoic acid receptor (RAR, for example, RARa) to form an active transcription factor complex able to activate homeotic genes. ATRA is the oxidised derivative of vitamin A (retinol) and Hox genes are induced by RAR/RXR (retinoid X receptor) þ ATRA complexes binding to retinoic acid response elements. Concentration gradients of Hox gene expression regulate anterior/posterior positioning during embryogenesis, and accordingly abnormal levels of ATRA are recognised as being highly teratogenic. 85 In development, endogenous ATRA is required for homeostasis in the immune system and for gut homing of T lymphocytes and their increased expression of Foxp3.
As ATRA promotes the Treg lineage, 81, 82, 84, [86] [87] [88] it is worth asking, is there any evidence for cross-regulation between ATRA and LIF? Importantly, LIF influences oxidative conversion of vitamin A to ATRA in mouse embryonic stem cell; 89 also, LIF synergises with ATRA in differentiation of neural precursor cells to astrocytes 90 and ATRA induces LIF expression in oligodendrocytes: 91 furthermore LIF is induced by ATRA in mouse embryonic stem cell. 92 Taken together these observations indicate inter-relationships between ATRA and LIF and convergent pathways on epigenetic development.
When considering therapy it is important to recall that ATRA-a nuclear hormone-enters cells directly and therapeutic use of ATRA is mainly restricted to topical application with the exception of treatment of acute myeloid leukaemia where ATRA induces differentiation of the immature replicating leukaemic cells. 93, 94 It is relevant to note that LIF also induces myeloid leukaemic cells to differentiate. 3 In contrast to ATRA, LIF as a therapeutic agent given at physiological doses functions as an extracellular cytokine without toxicity: the ability to target LIF to specific cell types and tissues in vivo, focussing therapy to sites of need, is the outstanding advantage of the nano-delivery system.
LIF nano-therapy
LIF as a therapeutic can be considered as combining two key biological properties: (i) support of Treg and (ii) promotion of tissue repair. Thus, LIF has powerful therapeutic potential not only for tolerance but also for protection of endogenous cells including tissue-resident adult stem cells.
The immediate barrier for LIF as a therapy is its rapid breakdown by serum proteases. However, delivery of LIF within a biodegradable nano-particulate carrier (LIFnano) targeted to CD4 þ T cells has proved efficacious in Treg induction without toxicity. 34, 69 The LIF-nano are constructed to provide a sustained low-level release of LIF to the immediate environment of the CD4 þ T cell in a paracrine fashion and it has been demonstrated that LIF-nano (i) oppose IL-6-driven Th17 development; (ii) prolong survival of vascularised heart grafts in mice; and (iii) expand FOXP3 þ CD4 þ T-cell numbers in a non-human primate model in vitro. 69 Moreover, using rat neural precursor cells, direct evidence of LIF-nanomediated expansion of dopaminergic neurons has been obtained. (Dyson, Metcalfe, Fahmy and Barker, unpublished experiments).
Notably, nanoparticle-mediated delivery was discovered to be important for Treg expansion. Neither unloaded nanoparticles targeted to CD4, nor soluble LIF, recapitulated the efficacy of LIF-nano in amplifying Foxp3 þ cell numbers 69 ( Figure 5 ). Application of targeted nanoparticles provides a powerful new access route not only to T-cell developmental plasticity in immune-mediated disease indications, but also for neuroprotection. By directly harnessing natural endogenous pathways, it is anticipated that the effects of LIF will become self-sustaining and self-regulating after the therapeutic particles have been totally degraded.
Does MARCH-7 provide a mechanism for the LIF/IL-6 axis? Figure 1 shows that the IL-6 receptor is composed of gp130/gp130 homodimers while the LIF receptor is qualified by the presence of gp190, forming gp130/gp190 heterodimers. On the basis of the LIF/IL-6 axis and the differential effects of LIF, versus IL-6, on T-cell differentiation it was argued that discrimination must be at the level of the receptor. MARCH-7, although originally described as a neural stem cell gene, has recently been discovered to be an E3-ligase required to degrade gp190 (Figure 6b) . 34 Using the MARCH-7 null mouse, it was found that MARCH-7 has profound and specific effects on T cells, being required to regulate T-cell activation thresholds and also to regulate levels of released soluble LIF protein, 95 summarised in Figure 6 . Overall MARCH-7 is a strong candidate to function in regulation of endogenous LIF signalling, acting as a rheostat to control cell surface expression levels of gp190:
this concept is in accord with the increased levels of gp190 protein found on activated CD4 þ MARCH-7 null T cells. 34 The recent discovery that lack of MARCH-7 has profound effects on LIF target gene expression, including Nanog, a core stem cell gene, has revealed a LIF/Nanog axis in T cells. 16 Here, it is proposed that Nanog is a LIF- . 34 (c) Lack of MARCH-7 in T cells activated by conA resulted in eightfold increase in proliferation and fivefold increase in LIF release compared with wt. These effects were specific to T cells and were gene dose-dependent. 95 response gene, with a LIF/Nanog axis becoming unmasked in T cells that lack MARCH-7. Regulation via MARCH-7, by influencing degradation of gp190, provides a natural rheostat-type mechanism for control of transcription of LIF-target genes. Such regulation will be sensitive to micro-environmental cues, because MARCH-7 is itself subject to modulation. For example, IL-6 strongly induces MARCH-7 transcripts in naive CD4 þ T cells, coinciding with both suppression of LIF transcription and induction of TH17 cells. 34 Thus, differential gene silencing during lineage development of peripheral naive T cells appears to be sensitive to levels of MARCH-7 activity. Figure 7 shows the altered kinetics of gene expression profiles in T cells lacking MARCH-7. Included is an adaptation of Niwa's model of embryonic stem cell signalling downstream from the LIF receptor: this adaptation shows the putative site of MARCH-7 activity to illustrate a purely personal theory of how lack of MARCH-7 might be linked to Nanog expression in T cells.
Does LIF reflect a state of 'stemness' in Treg?
Stem cells including mesenchymal stem cells are maintained in a pluripotent state by LIF and are immune privileged where LIF, but not IL-6, promotes stem cell expansion. [96] [97] [98] [99] [100] New insights enabled by powerful technologies to interrogate the genome have revealed that many aspects of lymphocyte development and regulation converge on stemness, providing plasticity and numerical flexibility for homeostasis of specific effector functions within a complex whole of wide ranging immune functions. A state of stemness has been proposed to underpin the peripheral development of the Treg lineage. 16, 95, 101 Here, endogenous LIF signalling would modulate the genomic plasticity of the newly activated T cell during amplification and lineage development in the context of micro-environmental cues, these cues in turn influencing MARCH-7 and LIF-R expression. In contrast to the effector T-cell lineages, Treg would become epigenetically stable in a relatively plastic state, this being perpetuated by release of endogenous LIF in response to antigen. Because LIF prevents further differentiation toward an immune aggressive phenotype, a stable feedback loop for antigen-specific tolerance is established. Yang et al. 102 have demonstrated molecular antagonism and plasticity of Treg and TH17 programs, while others show that for IL-6 to control Th17 immunity in vivo, inhibition of conversion of conventional T cells into Foxp3 regulatory T cells is required. 103 Although in these studies LIF itself was not explored, the findings Figure 7 Lack of MARCH-7 is permissive for Nanog expression in T cells. The right panel is copied with permission from Cell Cycle, 16 showing activation of Nanog in T cells that lack MARCH-7: here the kinetic profile gene expression is altered relative to specific phases of the T-cell cycle, with Nanog, LIF and IL-6 being specifically upregulated in G1. The left panel is adapted from Niwa et al. 7 showing pathways downstream of LIF in mouse embryonic stem cell (ESC): superimposed in the circle is an indication of where MARCH-7 would be expected to function in T cells according to references 16,95. It is speculated that, by regulating gp190, MARCH-7 in turn may be coupled to regulation of endogenous LIF signalling: in the absence of MARCH-7 increased LIF signalling may lead to the activation of Nanog, revealing a previously occult LIF/Nanog axis in T cells as described in Thompson et al. 16 build further support for the general concept that basic principles of cellular epigenetic plasticity operate within the specific constraints of T-cell phenotype maturation.
Summarising comments
This overview integrates multiple lines of evidence from various approaches to argue a central role for LIF in T-cell biology, with focus on the LIF/IL-6 axis. The implications are set in the wider context of the potential value of LIF as a therapeutic and how targeted LIF delivery may achieve this end. The extrapolations based on the reviewed data are those of the author, with the intention of provoking new inter-disciplinary approaches where LIF is seen a providing a pivotal link between immune regulation and immune-based therapies.
Note added in proof
In a recent study of cumulative genetic risk for multiple sclerosis from genome wide association data, an allelic variant of the IL6 gene was the sixth most significant marker. 
